Mostrar el registro sencillo del ítem
dc.contributor | Facultad de Veterinaria | es_ES |
dc.contributor.author | Porras Sanabria, David | |
dc.contributor.author | Nistal González, Maria Esther | |
dc.contributor.author | Martínez Flórez, Susana | |
dc.contributor.author | González Gallego, Javier | |
dc.contributor.author | García Mediavilla, María Victoria | |
dc.contributor.author | Sánchez Campos, Sonia | |
dc.contributor.other | Fisiologia | es_ES |
dc.date | 2018 | |
dc.date.accessioned | 2024-01-26T12:10:46Z | |
dc.date.available | 2024-01-26T12:10:46Z | |
dc.identifier.citation | Porras, D., Nistal González, E., Martínez-Flórez, S., González-Gallego, J., García-Mediavilla, M. V., & Sánchez-Campos, S. (2018). Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease [Review of Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease]. Frontiers in Physiology, 9. Frontiers Media S.A. https://doi.org/10.3389/FPHYS.2018.01813 | es_ES |
dc.identifier.other | https://www.frontiersin.org/articles/10.3389/fphys.2018.01813/full | es_ES |
dc.identifier.uri | https://hdl.handle.net/10612/17853 | |
dc.description.abstract | [EN] Obesity and associated comorbidities, including non-alcoholic fatty liver disease (NAFLD), are a major concern to public well-being worldwide due to their high prevalence among the population, and its tendency on the rise point to as important threats in the future. Therapeutic approaches for obesity-associated disorders have been circumscribed to lifestyle modifications and pharmacological therapies have demonstrated limited efficacy. Over the last few years, different studies have shown a significant role of intestinal microbiota (IM) on obesity establishment and NAFLD development. Therefore, modulation of IM emerges as a promising therapeutic strategy for obesity-associated diseases. Administration of prebiotic and probiotic compounds, fecal microbiota transplantation (FMT) and exercise protocols have shown a modulatory action over the IM. In this review we provide an overview of current approaches targeting IM which have shown their capacity to counteract NAFLD and metabolic syndrome features in human patients and animal models. | es_ES |
dc.language | eng | es_ES |
dc.publisher | Frontiers Media | es_ES |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Fisiología | es_ES |
dc.subject.other | Non-alcoholic fatty liver disease (NAFLD) | es_ES |
dc.subject.other | Obesity | es_ES |
dc.subject.other | Intestinal microbiota | es_ES |
dc.subject.other | Probiotics | es_ES |
dc.subject.other | Prebiotics | es_ES |
dc.subject.other | Polyphenols | es_ES |
dc.subject.other | Fecal microbiota transplantation (FMT) | es_ES |
dc.subject.other | Physical exercise | es_ES |
dc.title | Intestinal microbiota modulation in obesity-related non-alcoholic fatty liver disease | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | 10.3389/fphys.2018.01813 | |
dc.description.peerreviewed | SI | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/AEI/Programa Estatal de I+D+i Orientada a los Retos de la Sociedad/BFU2017-87960-R/ES/EFECTO DEL EJERCICIO FISICO Y QUERCETINA Y DEL TRASPLANTE DE MICROBIOTA INTESTINAL PROTECTORA O PREDISPONENTE ADICIONADA CON AKKERMANSIA MUCINIPHILA EN MODELOS DE NAFLD | es_ES |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es_ES |
dc.identifier.essn | 1664-042X | |
dc.journal.title | Frontiers in Physiology | es_ES |
dc.volume.number | 9 | es_ES |
dc.page.initial | 1813 | es_ES |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es_ES |
dc.subject.unesco | 3109.09 Fisiología | es_ES |
dc.subject.unesco | 32 Ciencias Médicas | es_ES |
dc.description.project | This work was supported by grants to JG-G and SS-C from Ministerio de Economía y Competitividad/FEDER (BFU2017- 87960-R) and Junta de Castilla y León (LE063U16 and GRS 1888/A/18). DP was supported by a fellowship from Junta de Castilla y León co-financed by the European Social Fund. EN was supported by Fundación de Investigación Sanitaria of León. MG-M was supported by CIBERehd contracts. CIBERehd is funded by the Instituto de Salud Carlos III, Spain. | es_ES |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
-
Artículos [5086]